Detechgene Launches DIAGURIN Project within Gesünder.IN.NRW

We are excited to share some great news: our project DIAGURIN has been selected for funding under Gesünder.IN.NRW, a program of the State of North Rhine-Westphalia (NRW) supported through the EFRE/JTF NRW initiative and coordinated by the Ministry of Economy, Industry, Climate Protection and Energy of NRW.

Within this framework, Detechgene will lead DIAGURIN, aiming to develop a novel diagnostic platform capable of simultaneously detecting protein and nucleic acid biomarkers in urine. This represents a major step toward non-invasive, precise, and patient-friendly early detection of autosomal dominant polycystic kidney disease (ADPKD). ADPKD is one of the most common hereditary kidney diseases, affecting around 80,000 people in Germany and over 12.5 million people worldwide, highlighting the urgent need for earlier and more personalized diagnostic solutions.

We are thrilled to carry out this project together with strong partners, including Fraunhofer IIS and Universitätsklinikum Düsseldorf, combining expertise from biotechnology, clinical research, and translational diagnostics.

By integrating biotechnology, digital biomarker analysis, and clinical expertise, DIAGURIN aims to unlock new possibilities for earlier detection and more personalized treatment strategies. The platform technology is designed to be scalable, opening the door for future diagnostic applications beyond kidney disease.

We are deeply grateful for the support from the State of North Rhine-Westphalia, which enables us to translate scientific excellence into real healthcare innovation while strengthening NRW as a leading hub for biotechnology and medical technology in Europe.

We look forward to advancing this project with our partners and bringing the next generation of diagnostics closer to patients.

‍